States that the United States Food and Drug Administration has approved a drug called gemcitabine, which will be used as a treatment for pancreatic cancer. Reason pancreatic cancer is considered as one of the leading cause of death in the United States; Discussion on the diagnosis of the ...
New drugs are also being developed to specifically target the stroma of the tumor. This includes pamrevlumab, which showed promising results in phase 1 and phase 2 trials for the treatment of locally advanced pancreatic cancer, mainly in the increase of patients who became resectable...
Drug Design, Development and Therapy Dovepress open access to scientific and medical research Open Access Full Text Article Review Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies This article was published in the following Dove Press journal: Drug Design, Development...
NMC-001 monoclonal antibody targets a specific pancreatic cancer marker and is able to selectively identify and diagnose pancreatic cancer in human. With a high affinity for its target, NMC-001 demonstrates potent anti-tumor efficiency in rodent models of pancreatic cancer. ...
Pancreatic cancer: current standards, working towards a new therapeutic approach. Expert Rev Anticancer Ther 14(5), 495-497.Olowokure O, Qi X. Pancreatic cancer: current standards, working towards a new therapeutic approach. Expert Rev Anticancer Ther. 2014;14:495–7. Central...
While many obstacles still exist, clearly we are making progress in deciphering the heterogeneity within pancreatic cancers. Integrating conventional and immunological targeting will be the key to effective treatment of this deadly disease. 展开 关键词: pancreatic cancer immunotherapies signaling pathway ...
癌症标志(hallmarks of cancer)的概念化对原创性研究工作具有启发性,可将癌症表型和基因型的巨大复杂性凝练成一系列的基本原则。近日,瑞士洛桑联邦理工学院的Douglas Hanahan在Cancer Discovery杂志上发表了癌症研究领域的年度重磅综述论文:Hallmarks of Cancer: New Dimensions,并被选为当期杂志封面。该综述论文将已建立...
Less than 5% of patients diagnosed with pancreatic cancer survive more than 5 years. Generally, the advanced stage, the late diagnosis and the poor therapeutic options are assumed to be responsible for this poor prognosis. Nonetheless, in recent years our knowledge of the pathogenesis of pancreatic...
IgG is the predominant antibody used in current antibody drugs, but in certain cases, the application of full-length antibody is limited in cancer treatment because these large antibodies such as poor penetration into solid tumors and because the Fc can mediate bystander activation of the immune sy...
"There's really been a paradigm shift for pancreatic cancer, now that we have better drugs," he said. Despite these improvements in treatment, pancreatic cancer is currently the fourth deadliest, and "it's climbing the ladder in terms of the number of people it kills," said Carl Schmidt,...